{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+analog&page=3", "query": { "intervention": "GnRH analog", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 140, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+analog&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+analog&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T11:02:29.047Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01546987", "title": "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "GnRH agonist", "type": "DRUG" }, { "name": "Anti-androgen", "type": "DRUG" }, { "name": "TAK-700", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 239, "start_date": "2012-05", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 165, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01546987" }, { "nct_id": "NCT00512668", "title": "Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" }, { "name": "nilutamide", "type": "DRUG" }, { "name": "flutamide", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 24, "start_date": "2007-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00512668" }, { "nct_id": "NCT04203381", "title": "Skeletal Health and Bone Marrow Composition Among Youth", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gender Dysphoria in Children", "Puberty", "Bone Development" ], "interventions": [ { "name": "GnRH Agonist", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Amy DiVasta, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "9 Years to 14 Years" }, "enrollment_count": 78, "start_date": "2020-09-15", "completion_date": "2026-03-30", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04203381" }, { "nct_id": "NCT03388619", "title": "Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer Of Prostate", "Prostate Neoplasms", "Prostate Cancer", "Neoplasms of Prostate", "Prostatic Cancer" ], "interventions": [ { "name": "Prostate bed with integrated boost", "type": "RADIATION" }, { "name": "Prostate bed irradiation only", "type": "RADIATION" }, { "name": "Whole Body Bone Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-NaF PET Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "mpMRI", "type": "DIAGNOSTIC_TEST" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2018-01-17", "completion_date": "2025-12-04", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03388619" }, { "nct_id": "NCT03141671", "title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "GnRH", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Salvage radiation", "type": "RADIATION" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "MALE", "summary": "18 Years to 95 Years · Male only" }, "enrollment_count": 345, "start_date": "2017-11-24", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 8, "location_summary": "San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141671" }, { "nct_id": "NCT07027124", "title": "Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "High-risk Prostate Cancer" ], "interventions": [ { "name": "Darolutamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lupron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2026-05-21", "completion_date": "2031-05-02", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07027124" }, { "nct_id": "NCT01116401", "title": "Impact of Hot Flashes on Sleep and Mood Disturbance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menopause", "Depression", "Hot Flashes" ], "interventions": [ { "name": "leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 29, "start_date": "2009-11-03", "completion_date": "2012-01-04", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116401" }, { "nct_id": "NCT05567198", "title": "Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus (Sle)", "Primary Ovarian Insufficiency (Poi)" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 100, "start_date": "2023-03-03", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05567198" }, { "nct_id": "NCT02058706", "title": "LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" }, { "name": "orchiectomy", "type": "PROCEDURE" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 71, "start_date": "2014-05", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058706" }, { "nct_id": "NCT03275181", "title": "Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Transthoracic Echocardiography", "type": "DIAGNOSTIC_TEST" }, { "name": "Arterial blood pressure", "type": "DIAGNOSTIC_TEST" }, { "name": "Submaximal Exercise", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Kansas State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "21 Years to 80 Years · Male only" }, "enrollment_count": 18, "start_date": "2017-08-01", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-05T11:02:29.047Z", "location_count": 1, "location_summary": "Manhattan, Kansas", "locations": [ { "city": "Manhattan", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275181" } ] }